Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Receivables (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Receivables for 16 consecutive years, with $7000.0 as the latest value for Q3 2025.

  • Quarterly Change in Receivables rose 40.0% to $7000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $10000.0 through Sep 2025, up 102.94% year-over-year, with the annual reading at $8000.0 for FY2025, 102.54% up from the prior year.
  • Change in Receivables for Q3 2025 was $7000.0 at IGC Pharma, up from -$2000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $324000.0 in Q1 2022, with the low at -$301000.0 in Q1 2024.
  • Average Change in Receivables over 5 years is -$117.65, with a median of $5000.0 recorded in 2024.
  • The sharpest move saw Change in Receivables tumbled 675.0% in 2021, then skyrocketed 3800.0% in 2022.
  • Over 5 years, Change in Receivables stood at $2000.0 in 2021, then surged by 3800.0% to $78000.0 in 2022, then crashed by 156.41% to -$44000.0 in 2023, then soared by 111.36% to $5000.0 in 2024, then surged by 40.0% to $7000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $7000.0, -$2000.0, and $5000.0 for Q3 2025, Q1 2025, and Q4 2024 respectively.